Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled - Université de Lorraine Access content directly
Journal Articles European Heart Journal Year : 2022

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

Javed Butler
Ivana Ritter
Elke Schüler
  • Function : Author

Abstract

Abstract Aims Hyperkalaemia frequently leads to interruption and discontinuation of neurohormonal antagonists, which may worsen heart failure prognosis. Some studies suggested that sodium-glucose cotransporter 2 inhibitors reduce hyperkalaemia, an effect that may have important clinical implications. This analysis evaluates the effect of empagliflozin on the occurrence of hyper- and hypokalaemia in HF. Methods and results EMPEROR-Pooled (i.e. EMPEROR-Reduced and EMPEROR-Preserved combined) included 9583 patients with available serum potassium levels at baseline (98.6% of the total EMPEROR-Pooled population, n = 9718). Hyperkalaemia was identified by investigators’ reports of adverse events, and by a laboratory serum potassium value above 5.5 mmol/L and 6.0 mmol/L. The main outcome was a composite of investigator-reported hyperkalaemia or initiation of potassium binders. Patients with high potassium at baseline were more frequently diagnosed with diabetes and ischaemic HF aetiology and had lower left ventricular ejection fraction and estimated glomerular filtration rate but were more frequently treated with sacubitril/valsartan or mineralocorticoid receptor antagonists. Empagliflozin (compared with placebo) reduced the composite of investigator-reported hyperkalaemia or initiation of potassium binders [6.5% vs. 7.7%, hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71–0.95, P = 0.01]. Empagliflozin reduced hyperkalaemia rates regardless of the definition used (serum potassium >5.5 mmol/l: 8.6% vs. 9.9%, HR 0.85, 95% CI 0.74–0.97, P = 0.017; serum potassium >6.0 mmol/l: 1.9% vs. 2.9%, HR 0.62, 95% CI 0.48–0.81, P < 0.001). The incidence of hypokalaemia (investigator-reported or serum potassium <3.0 mmol/l) was not significantly increased with empagliflozin. Conclusions Empagliflozin reduced the incidence of hyperkalaemia without significant increase in hypokalaemia.
Fichier principal
Vignette du fichier
ehac306.pdf (942.05 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03694153 , version 1 (13-06-2022)

Licence

Attribution - NonCommercial

Identifiers

Cite

João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filipattos, Ivana Ritter, et al.. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal, 2022, 43 (31), pp.2984-2993. ⟨10.1093/eurheartj/ehac306⟩. ⟨hal-03694153⟩
39 View
82 Download

Altmetric

Share

Gmail Facebook X LinkedIn More